			December 31,
			2020								2019
	Weighted Average Amortization Period (in years)		Cost		Accumulated Amortization		Impairment		Net		Cost		Accumulated Amortization		Impairment		Net
Definite-lived intangible assets:
Patent		—	$	669	$	131	$	538	$	—	$	716	$	99	$	—	$	617
Customer relationships		16		138,885		16,030		—		122,855		135,953		7,132		—		128,821
Developed technology		10		7,227		1,325		—		5,902		7,074		590		—		6,484
Websites		3		5,332		4,348		—		984		5,157		3,331		—		1,826
Trademarks and licenses		5		9,009		1,245		7,650		114		9,135		925		—		8,210
Total				161,122		23,079		8,188		129,855		158,035		12,077		—		145,958
Indefinite‑lived intangible assets:
Cultivation license		—		10,239		—		10,239		—		10,689		—		—		10,689
Alef license		—		—		—		—		—		4,086		—		4,086		—
Trademarks	Indefinite			56,590		—		—		56,590		55,416		—		—		55,416
Rights under ABG Profit Participation Arrangement		—		16,765		—		16,765		—		119,366		—		102,601		16,765
Total				83,594		—		27,004		56,590		189,557		—		106,687		82,870
Total intangible assets			$	244,716	$	23,079	$	35,192	$	186,445	$	347,592	$	12,077	$	106,687	$	228,828

In connection with the Company’s closure of its High Park Gardens facility, the Company determined that the fair value of the indefinite-lived cultivation license was below carrying value. As a result, the Company incurred non-cash impairment charges of $10,239, representing the full net book value of the cultivation license, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 3).

In connection with the decreased demand projections of CBD products in the United States resulting in a reduced estimate of future cash flows, during the first quarter of 2020 the Company determined that the fair value of indefinite-lived rights under the ABG Profit Participation Arrangement and definite-lived trademarks under the Trademark and License Agreement with ABG for the use of the Prince trademark (“ABG Prince Agreement”) were below the carrying value. As a result, the Company incurred non-cash impairment charges of $16,765 and $6,063 representing the full net book values of the intangible assets relating to the ABG Profit Participation Agreement and ABG Prince Agreement respectively, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 4). In June 2020, the Company completed the separation from Smith & Sinclair and recognized additional non-cash impairment charges of $3,320 presented in impairment of assets in the statement of net loss and comprehensive loss, of which $2,126 related to other CBD trademarks and patents.

Amortization expenses for intangibles was $11,002, $9,824, and $374 in 2020, 2019, and 2018, respectively. Expected future amortization expenses for intangible assets as of December 31, 2020 are as follows: 2021 – $10,222; 2022 – $9,744; 2023 - $9,500; 2024 - $9,493, 2025 – $9,469; and thereafter – $81,427.